BSEM (BioStem Technologies) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2025)

What is BioStem Technologies LT-Debt-to-Total-Asset?

BioStem Technologies BSEM -5.17% 49 LT-Debt-to-Total-Asset is 0.00 as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $141.44 (Possible Value Trap). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioStem Technologies's long-term debt to total assests ratio for the quarter that ended in Sep. 2025 was 0.00.

BioStem Technologies's long-term debt to total assets ratio declined from Sep. 2023 (0.24) to Sep. 2025 (0.00). It may suggest that BioStem Technologies is progressively becoming less dependent on debt to grow their business.

BioStem Technologies (OTCPK:BSEM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioStem Technologies LT-Debt-to-Total-Asset Related Terms

BioStem Technologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies LT-Debt-to-Total-Asset Chart

BioStem Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.64

0.68

0.30

0.02

0.00

BioStem Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Sep21	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Sep24	Dec24	Sep25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.24	0.02	0.00	0.00	0.00

49GF Score

BioStem Technologies Inc BSEM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioStem Technologies LT-Debt-to-Total-Asset Calculation

BioStem Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.33	/	140.376
	=	0.00

BioStem Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (Q: Sep. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2025 )	/	Total Assets (Q: Sep. 2025 )
	=	0.158	/	62.393
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

BioStem Technologies (BSEM) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioStem Technologies and its competitors.

Is BioStem Technologies' LT-Debt-to-Total-Asset too high?

BioStem Technologies' current LT-Debt-to-Total-Asset is 0.00. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does BioStem Technologies' LT-Debt-to-Total-Asset compare to XLO and TCRX?

BioStem Technologies' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioStem Technologies stock overvalued right now?

Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $141.44, compared to a current price of $3.30 — trading 97.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.30 is trading 97.7% below its estimated GF Value™ of $141.44. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $141.44 vs. price of $3.30 (97.7% below fair value)
GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Industry Healthcare Biotechnology

Comparable Companies XLO TCRX MNOV PMVP FLNA BOLD INKT DWTX CING IMA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064

Website https://www.biostemtechnologies.com

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

49GF Score

Get the complete analysis for BSEM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30

Price

$141.44

GF Value

View BSEM Analysis

See LT-Debt-to-Total-Asset data for all stocks →